ITCI Intra-Cellular Therapies Inc

Price (delayed)

$58.25

Market cap

$5.49B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$3.64

Enterprise value

$5.39B

Intra-Cellular Therapies is a biopharmaceutical company founded on Nobel prize-winning research that allows us to understand how therapies affect the inner-workings of cells in the body. The company leverages this ...

Highlights
The revenue has soared by 174% YoY and by 23% from the previous quarter
The gross profit has soared by 171% YoY and by 23% from the previous quarter
ITCI's quick ratio has soared by 68% from the previous quarter but it is down by 14% YoY
The net income is down by 31% YoY and by 7% from the previous quarter
The EPS has contracted by 16% YoY and by 4% from the previous quarter

Key stats

What are the main financial stats of ITCI
Market
Shares outstanding
94.32M
Market cap
$5.49B
Enterprise value
$5.39B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
6.88
Price to sales (P/S)
52.41
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
52.35
Earnings
Revenue
$102.92M
EBIT
-$303.5M
EBITDA
-$302.92M
Free cash flow
-$295.52M
Per share
EPS
-$3.64
Free cash flow per share
-$3.19
Book value per share
$8.47
Revenue per share
$1.11
TBVPS
$9.38
Balance sheet
Total assets
$868.58M
Total liabilities
$75.83M
Debt
$24.39M
Equity
$792.75M
Working capital
$789.27M
Liquidity
Debt to equity
0.03
Current ratio
14.36
Quick ratio
13.65
Net debt/EBITDA
0.35
Margins
EBITDA margin
-294.3%
Gross margin
90.5%
Net margin
-294.9%
Operating margin
-296.5%
Efficiency
Return on assets
-47.8%
Return on equity
-53.9%
Return on invested capital
-61.4%
Return on capital employed
-37.5%
Return on sales
-294.9%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ITCI stock price

How has the Intra-Cellular Therapies stock price performed over time
Intraday
5.47%
1 week
7.33%
1 month
-0.05%
1 year
46.54%
YTD
11.29%
QTD
-4.8%

Financial performance

How have Intra-Cellular Therapies's revenue and profit performed over time
Revenue
$102.92M
Gross profit
$93.19M
Operating income
-$305.13M
Net income
-$303.5M
Gross margin
90.5%
Net margin
-294.9%
The revenue has soared by 174% YoY and by 23% from the previous quarter
The gross profit has soared by 171% YoY and by 23% from the previous quarter
The operating margin has soared by 53% YoY and by 13% from the previous quarter
The net margin has surged by 52% year-on-year and by 13% since the previous quarter

Growth

What is Intra-Cellular Therapies's growth rate over time

Valuation

What is Intra-Cellular Therapies stock price valuation
P/E
N/A
P/B
6.88
P/S
52.41
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
52.35
The EPS has contracted by 16% YoY and by 4% from the previous quarter
The equity has surged by 90% since the previous quarter and by 30% year-on-year
ITCI's P/B is 63% above its 5-year quarterly average of 4.0 but 12% below its last 4 quarters average of 7.4
The revenue has soared by 174% YoY and by 23% from the previous quarter
The stock's price to sales (P/S) is 100% less than its 5-year quarterly average of 19323.6 and 4.6% less than its last 4 quarters average of 52.1

Efficiency

How efficient is Intra-Cellular Therapies business performance
The ROS has soared by 52% YoY and by 13% from the previous quarter
The ROE has contracted by 37% YoY
Intra-Cellular Therapies's ROA has decreased by 34% YoY
ITCI's return on invested capital is down by 28% year-on-year but it is up by 2.4% since the previous quarter

Dividends

What is ITCI's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ITCI.

Financial health

How did Intra-Cellular Therapies financials performed over time
Intra-Cellular Therapies's total assets has soared by 77% from the previous quarter and by 29% YoY
ITCI's quick ratio has soared by 68% from the previous quarter but it is down by 14% YoY
The debt is 97% smaller than the equity
The equity has surged by 90% since the previous quarter and by 30% year-on-year
ITCI's debt to equity has dropped by 50% since the previous quarter and by 40% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.